AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6226480 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with a mixture of 2.5 mg nickel, 2.5 mg chromium, and 1 mg cobalt salts
Number of subjects: 202
Study 6226480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet planned to reduce daily intake of respective metals
Number of subjects: 202
Study 6226480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet adherence
Number of subjects: 202
Study 30747604 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose (D-psicose)
Number of subjects: 0
Study 30747604 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tagatose
Number of subjects: 0
Study 30747604 — intervention group
Group type: EXPERIMENTAL
Intervention: D-sorbose
Number of subjects: 0
Study 30747604 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allose
Number of subjects: 0
Study 30747604 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural sweeteners (stevia, monk fruit)
Number of subjects: 0
Study 30747604 — intervention group
Group type: COMPARATOR
Intervention: Artificial sweeteners
Number of subjects: 0
Study 28732525 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 hours of simulated placement
Number of subjects: 0
Study 28732525 — intervention group
Group type: COMPARATOR
Intervention: 40 hours of traditional placement
Number of subjects: 0
Study 28732525 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated placement
Number of subjects: 0
Study 28732525 — intervention group
Group type: COMPARATOR
Intervention: Traditional placement
Number of subjects: 0
Study 26372082 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-sized food portions with modest nonfood incentives (e.g., inexpensive headphones for children, gift cards or frequent flyer miles for adults, small amounts of money for restaurant customers)
Number of subjects: 0
Study 26372082 — intervention group
Group type: COMPARATOR
Intervention: Full-sized food portions without nonfood incentives
Number of subjects: 0
Study 22954666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25mg daily) alone
Number of subjects: 2603
Study 22954666 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20mg daily) followed by exemestane
Number of subjects: 2603
Study 22954666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane (25mg daily)
Number of subjects: 2603
Study 21082252 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention for 7 months
Number of subjects: 198
Study 19846851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin alone (80 mg/m² every 14 days)
Number of subjects: 255
Study 19846851 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus doxorubicin (administered in three preoperative cycles and two postoperative cycles)
Number of subjects: 255
Study 18027183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethylcellulose inserts of niridazole
Number of subjects: 0
Study 18027183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15999036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion (washed salvaged red blood cells)
Number of subjects: 61
Study 15999036 — intervention group
Group type: COMPARATOR
Intervention: Control (homologous blood only)
Number of subjects: 61
Study 12432291 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal sphincterotomy
Number of subjects: 42
Study 12432291 — intervention group
Group type: COMPARATOR
Intervention: No internal sphincterotomy
Number of subjects: 42
Study 10673919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive film dressing covering the nipple-areolar complex
Number of subjects: 25
Study 10673919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no shields)
Number of subjects: 25
Study 8942462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine augmentation
Number of subjects: 33
Study 8942462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 1887483 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/d for 30 d
Number of subjects: 100
Study 1887483 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel 50 mg/kg/d for 15 d
Number of subjects: 100
Study 6138064 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 12
Study 6138064 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 20 mg
Number of subjects: 12
Study 6138064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31698695 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich mixed berry smoothie (400 mL) containing equal amounts of blueberry, strawberry, raspberry, and blackberry, n = 20
Number of subjects: 40
Study 31698695 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo smoothie, n = 20
Number of subjects: 40
Study 30394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult access to healthcare (problems with distance/travel cost, history of moving residence in the past year)
Number of subjects: 264
Study 30394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of TB knowledge (lack of knowledge about TB transmission, cause of TB, unawareness of consequences of stopping treatment)
Number of subjects: 264
Study 30394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment experience (lack of TB education provided by TB nurse, use of loose vs. fixed-dose combinations)
Number of subjects: 264
Study 30394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Being aged under 35 years
Number of subjects: 264
Study 30394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a history of TB in the family
Number of subjects: 264
Study 27173807 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Well with Asthma website access for minimum 12 weeks
Number of subjects: 51
Study 27173807 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 24534073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >8 and ≤10 μmol/L
Number of subjects: 10000
Study 24534073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >10 and ≤13 μmol/L
Number of subjects: 10000
Study 24534073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin levels >13 μmol/L
Number of subjects: 10000
Study 24534073 — intervention group
Group type: COMPARATOR
Intervention: Total bilirubin levels ≤8 μmol/L
Number of subjects: 10000
Study 22878452 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of sodium hyaluronate and diquafosol tetrasodium
Number of subjects: 32
Study 22878452 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate monotherapy
Number of subjects: 32
Study 20650358 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1518
Study 17379049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine 20 mg + dimenhydrinate 40 mg
Number of subjects: 246
Study 17379049 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine 50 mg
Number of subjects: 246
Study 17379049 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate 100 mg
Number of subjects: 246
Study 17379049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 15733880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (3 times a week for 12 weeks)
Number of subjects: 212
Study 15733880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 212
Study 15733880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 212
Study 15733880 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 12019378 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-enhanced cardioplegia (10 IU/L insulin)
Number of subjects: 1127
Study 12019378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1127
Study 10219332 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of filgrastim (5 micrograms/kg) starting +1 day postchemotherapy
Number of subjects: 18
Study 10219332 — intervention group
Group type: COMPARATOR
Intervention: Delayed administration of filgrastim (5 micrograms/kg) starting +5 days postchemotherapy
Number of subjects: 18
Study 10219332 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of filgrastim
Number of subjects: 18
Study 10219332 — intervention group
Group type: COMPARATOR
Intervention: Delayed administration of filgrastim
Number of subjects: 18
Study 10150846 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields
Number of subjects: 0
Study 10150846 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection
Number of subjects: 0
Study 2163450 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg once daily
Number of subjects: 19
Study 2163450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, 10 mg once daily
Number of subjects: 19
Study 2163450 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study 661731 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg highly purified dextrothyroxine for 12 weeks
Number of subjects: 22
Study 661731 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg beta‐pyridylcarbinol for 12 weeks
Number of subjects: 22
Study 661731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 4 mg dextrothyroxine and 600 mg beta‐pyridylcarbinol daily for 8 weeks
Number of subjects: 22
Study 661731 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with dextrothyroxine
Number of subjects: 22
Study 661731 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with beta‐pyridylcarbinol
Number of subjects: 22
Study 661731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of dextrothyroxine and beta‐pyridylcarbinol
Number of subjects: 22
Study 30063556 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Training with Partial Vascular Occlusion (LI-BFR)
Number of subjects: 28
Study 30063556 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Resistance Training (HI-RT)
Number of subjects: 28
Study 29402870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment (MBT) in combination with SUD treatment, n = 24
Number of subjects: 46
Study 29402870 — intervention group
Group type: COMPARATOR
Intervention: SUD treatment alone, n = 22
Number of subjects: 46
Study 27393009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin (100 μg)
Number of subjects: 75
Study 27393009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 24717363 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (RWB)
Number of subjects: 19
Study 24717363 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined rye bread (RRB)
Number of subjects: 19
Study 24717363 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐meal rye bread (WRB)
Number of subjects: 19
Study 22585389 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful metaphorical story
Number of subjects: 0
Study 22585389 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful metaphorical story
Number of subjects: 0
Study 22585389 — intervention group
Group type: COMPARATOR
Intervention: Nonmetaphorical expression
Number of subjects: 0
Study 20843313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection and counselling intervention (personal advice to parents to prevent smoke exposure, referral to general practitioner or asthma nurse)
Number of subjects: 7893
Study 20843313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection and counselling intervention
Number of subjects: 7893
Study 20843313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7893
Study 18172067 — intervention group
Group type: EXPERIMENTAL
Intervention: First-eye cataract surgery
Number of subjects: 306
Study 15892532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealants with a bonding agent
Number of subjects: 30
Study 15892532 — intervention group
Group type: COMPARATOR
Intervention: Sealants without a bonding agent
Number of subjects: 30
Study 12510039 — intervention group
Group type: COMPARATOR
Intervention: Two infusions of 6 mg of natalizumab per kilogram
Number of subjects: 248
Study 12510039 — intervention group
Group type: EXPERIMENTAL
Intervention: Two infusions of 3 mg of natalizumab per kilogram
Number of subjects: 248
Study 12510039 — intervention group
Group type: EXPERIMENTAL
Intervention: All natalizumab groups
Number of subjects: 248
Study 12510039 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups receiving two infusions of natalizumab
Number of subjects: 248
Study 12510039 — intervention group
Group type: COMPARATOR
Intervention: All four groups
Number of subjects: 248
Study 10394423 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52
Study 10394423 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 52
Study 8834062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulation (e.g., warfarin)
Number of subjects: 100
Study 8834062 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 100
Study 8834062 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 100
Study 8834062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation management systems
Number of subjects: 100
Study 8834062 — intervention group
Group type: EXPERIMENTAL
Intervention: INR level management
Number of subjects: 100
Study 1829981 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (1 x 100 mg/day)
Number of subjects: 24
Study 1829981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1 x 2.5 mg/day)
Number of subjects: 24
Study 1829981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 6410908 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 80 mg intravenously plus Vivonex‐HN, 2 L/day po
Number of subjects: 24
Study 6410908 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone 80 mg intravenously plus total parenteral nutrition, 2.5 L/day
Number of subjects: 24
Study 6410908 — intervention group
Group type: EXPERIMENTAL
Intervention: total parenteral nutrition, 2.5 L/day
Number of subjects: 24
Study 6410908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivonex‐HN, 2 L/day po
Number of subjects: 24
Study 30910388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (maintenance of sinus rhythm by catheter ablation and/or antiarrhythmic drugs)
Number of subjects: 283
Study 30910388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control (maintenance of sinus rhythm)
Number of subjects: 283
Study 30910388 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 283
Study 29527702 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil once a day for 6 weeks
Number of subjects: 100
Study 29527702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral multivitamin tablet) once a day for 6 weeks
Number of subjects: 100
Study 27630326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil, epirubicin and cyclophosphamide followed by docetaxel
Number of subjects: 3754
Study 27630326 — intervention group
Group type: COMPARATOR
Intervention: FEC followed by docetaxel plus gemcitabine
Number of subjects: 3754
Study 27630326 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 vs. 5 years of treatment with zoledronic acid
Number of subjects: 3754
Study 27630326 — intervention group
Group type: EXPERIMENTAL
Intervention: CA27.29 and CTC positivity association
Number of subjects: 3754
Study 24290600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately restricted carbohydrate (MRC) diet
Number of subjects: 30
Study 22359079 — intervention group
Group type: EXPERIMENTAL
Intervention: Designed slippers splints
Number of subjects: 30
Study 22359079 — intervention group
Group type: COMPARATOR
Intervention: Market splints (including night splints and interdigital pads)
Number of subjects: 30
Study 20054553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 20 mg/40 ml saline
Number of subjects: 303
Study 20054553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 50 mg/100 ml
Number of subjects: 303
Study 20054553 — intervention group
Group type: COMPARATOR
Intervention: TUR alone (Control)
Number of subjects: 303
Study 18270335 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 5170
Study 18270335 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5170
Study 16708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Jianweiyuyang granules and ranitidine capsules
Number of subjects: 120
Study 16708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianweiyuyang granules
Number of subjects: 120
Study 16708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine capsules
Number of subjects: 120
Study 16708818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peptic ulcers)
Number of subjects: 120
Study 12843349 — intervention group
Group type: EXPERIMENTAL
Intervention: BFV measurements using the new ultrasonic device
Number of subjects: 23
Study 12843349 — intervention group
Group type: EXPERIMENTAL
Intervention: Total BFV value obtained from both ICAs
Number of subjects: 23
Study 12843349 — intervention group
Group type: EXPERIMENTAL
Intervention: BFV value of 220 mL/min
Number of subjects: 23
Study 12843349 — intervention group
Group type: EXPERIMENTAL
Intervention: BFV sensitivity and specificity for hyperemic range
Number of subjects: 23
Study 11063163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 180
Study 11063163 — intervention group
Group type: COMPARATOR
Intervention: Sedation with intravenous saline (placebo group)
Number of subjects: 180
Study 11063163 — intervention group
Group type: COMPARATOR
Intervention: No intravenous cannula (control group)
Number of subjects: 180
Study 9305489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 60 mg (2 x 30 mg suppositories)
Number of subjects: 32
Study 9305489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8327649 — intervention group
Group type: EXPERIMENTAL
Intervention: Instituto Butantan antivenom
Number of subjects: 121
Study 8327649 — intervention group
Group type: EXPERIMENTAL
Intervention: Instituto Vital Brazil antivenom
Number of subjects: 121
Study 8327649 — intervention group
Group type: EXPERIMENTAL
Intervention: FUNED antivenom
Number of subjects: 121
Study 8327649 — intervention group
Group type: COMPARATOR
Intervention: All three antivenoms
Number of subjects: 121
Study 3555063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 3981
Study 3555063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily
Number of subjects: 3981
Study 3555063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 3981
Study 29621048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue pressure strength and accuracy training (TPSAT) with traditional dysphagia therapy for 30 minutes each per day, 5 times per week for 8 weeks
Number of subjects: 16
Study 29621048 — intervention group
Group type: COMPARATOR
Intervention: Traditional dysphagia therapy for 30 minutes twice a day, 5 times per week for 8 weeks
Number of subjects: 16
Study 28237859 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus monthly lifestyle group education sessions of 45min duration
Number of subjects: 223
Study 28237859 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 223
Study 26174128 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 μg
Number of subjects: 50
Study 26174128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23292558 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 0
Study 23292558 — intervention group
Group type: COMPARATOR
Intervention: No mouth rinse (Control)
Number of subjects: 0
Study 23292558 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) treatment
Number of subjects: 0
Study 21631568 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day (CX2)
Number of subjects: 12
Study 21631568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 18053781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilio-inguinal nerve block with ropivicaine
Number of subjects: 12
Study 18053781 — intervention group
Group type: COMPARATOR
Intervention: Wound irrigation with ropivicaine
Number of subjects: 12
Study 18053781 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control for ilio-inguinal nerve block)
Number of subjects: 12
Study 18053781 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control for wound irrigation)
Number of subjects: 12
Study 16602577 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 95
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by stem-cell rescue
Number of subjects: 0
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem transplantation
Number of subjects: 0
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha and glucocorticoids
Number of subjects: 0
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and immunomodulatory derivatives
Number of subjects: 0
Study 13677263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 10709881 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids in mothers' milk
Number of subjects: 19
Study 9092744 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-UVB treatment
Number of subjects: 100
Study 9092744 — intervention group
Group type: COMPARATOR
Intervention: Conventional psoralen-UVA treatment
Number of subjects: 100
Study 8458681 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ29,852 (mean dose 15.0 ± 5.1 mg/day)
Number of subjects: 46
Study 8458681 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (mean dose 37.5 ± 18.5 mg/day)
Number of subjects: 46